betting all on the pharma industry. Ajay Piramal’s sharp business acumen helped him transform the Piramal Group into a multinational conglomerate with businesses ranging from pharmaceuticals ...

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 * global development and manufacturing facilities and a global ...

Piramal Pharma Limited said, "FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Piramal Pharma Ltd. announced a net profit of ₹3.7 crore in Q3 FY25, against ₹10.1 crore in the corresponding period in FY24, after decreasing 63.4% YoY. Operating revenues of ₹2,204.2 crore ...

Piramal Pharma Limited was incorporated on March 4 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Q3 Results, Earnings Today: Today, majors like Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Alembic Pharma, Castrol India, Taj GVK Hotels & Resorts, and others are releasing their ...

Rights Aug 02, 2023 Aug 02, 2023 Feb 08, 2023 Rights ratio: 5 share for every 46 held at a price of Rs 81.0 ...